ストックスクリーナーアプリを入手
184.74
1.40%
-2.63
アフターアワーズ：
184.74
前日終値:
$187.37
開ける：
$185.45
24時間の取引高:
1.79M
Relative Volume:
0.76
時価総額：
$286.50B
収益：
$60.48B
当期純損益:
$10.40B
株価収益率:
55.48
EPS:
3.3297
ネットキャッシュフロー:
$8.05B
1週間 パフォーマンス:
-2.64%
1か月 パフォーマンス:
-7.97%
6か月 パフォーマンス:
+124.20%
1年 パフォーマンス:
+162.01%
1日の値動き範囲:
$184.01
$187.18
1週間の範囲:
$181.73
$190.59
52週間の値動き範囲:
$66.16
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 5.96B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
Astrazeneca Plc $AZN Shares Sold by D.A. Davidson & CO. - MarketBeat
UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weigh - marketscreener.com
UK's FTSE 100 Closes Lower; NatWest, AstraZeneca Shares Down - marketscreener.com
Employee share plans add 14,807 AstraZeneca (AZN) shares to LSE - Stock Titan
FDA advisory committee does not support AstraZeneca’s camizestrant for breast cancer - Investing.com
AstraZeneca (AZN) Stock Drops as Breast Cancer Drug Fails to Win Over FDA Advisors - CoinCentral
FDA advisory panel recommends AstraZeneca’s Truqap for PTEN-deficient prostate cancer - Investing.com Nigeria
FDA panel opposes benefit-risk profile of AstraZeneca (AZN) camizestrant combo - Stock Titan
FDA panel supports AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient prostate cancer - Stock Titan
FTSE 100 drops in thin trading as NatWest, AstraZeneca weigh - Moneycontrol.com
AstraZeneca wins FDA AdCom backing for Truqap (AZN:NYSE) - Seeking Alpha
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters - Benzinga
AstraZeneca (NYSE: AZN) Posts Revenue Above $15bn in Q1 - Value The Markets
AstraZeneca Faces Setback as Drug Review Stirs Market Focus - Kalkine Media
AstraZeneca shares drop after US regulators vote against breast cancer drug - marketscreener.com
Why is AstraZeneca stock down today? - Traders Union
AstraZeneca falls as FDA advisers reject breast cancer drug use - Proactive financial news
AstraZeneca Shares Weaken After FDA Panel Rejects Camizestrant - Yahoo Finance UK
AstraZeneca PLC expected to post earnings of $2.58 a shareEarnings Preview - TradingView
AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote -- Update - marketscreener.com
AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant By Investing.com - Investing.com Nigeria
AstraZeneca shares drop after US regulatory panel votes against breast cancer drug - Reuters
AstraZeneca shares dip after US regulatory panel rejects breast cancer drug - marketscreener.com
US FDA Committee Votes Against Combination Formulation Featuring AstraZeneca's Camizestrant - marketscreener.com
AstraZeneca's Truqap Recommended by US FDA's Oncologic Drugs Committee - marketscreener.com
AstraZeneca : Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer - marketscreener.com
Alger Growth & Income Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca says Truqap recommended by FDA advisory committee for prostate cancer - marketscreener.com
ASTRAZENECA : Jefferies reiterates its Buy rating - marketscreener.com
ASTRAZENECA : Receives a Buy rating from JP Morgan - marketscreener.com
FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug - marketscreener.com
FDA panel rejects risk-benefit profile of AstraZeneca cancer drug - Reuters
FDA Panel Votes Against Benefit of Astra’s Breast Cancer Drug - Bloomberg.com
AstraZeneca Is a Buy as More Than 20 Phase III Readouts Loom - 24/7 Wall St.
FDA panel votes against backing AstraZeneca's breast cancer drug - marketscreener.com
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
AstraZeneca's Breast Cancer Drug Rejected by FDA on Safety Concerns, Bloomberg Reports - marketscreener.com
AstraZeneca Earnings: Off to a Great Start, With Major Readouts Expected Throughout the Year - Morningstar Canada
Astrazeneca exercises option for Pinetree’s PTX-299 - BioWorld News
Citi raises AstraZeneca earnings forecast and maintains 'buy' rating ahead of second-half pipeline catalysts - Proactive financial news
AstraZeneca Outlook Strengthens on Pipeline Momentum - Kalkine Media
ASTRAZENECA : Deutsche Bank reaffirms its Sell rating - marketscreener.com
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca - Quantisnow
AstraZeneca results: Q1 2026 - Quantisnow
AstraZeneca PLC (AZN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
EBIT per share of AstraZeneca PLC – HAM:ZEG - TradingView
Astrazeneca injects £300m into UK sites - marketscreener.com
Astrazeneca Q1 Earnings Call Highlights - Yahoo Finance
AstraZeneca takes global rights to an EGFR cancer drug in $25M deal - Stock Titan
AstraZeneca CEO says US MFN policy will have substantial impact on European drug launches, pricing - marketscreener.com
Correction to AstraZeneca Update - marketscreener.com
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
2.73%
大文字化:
|
ボリューム (24 時間):